2024
Association of early dexmedetomidine exposure with brain injury biomarker levels following moderate – Severe traumatic brain injury: A TRACK-TBI study
Wongsripuemtet P, Ohnuma T, Temkin N, Barber J, Komisarow J, Manley G, Hatfield J, Treggiari M, Colton K, Sasannejad C, Chaikittisilpa N, Ivins-O’Keefe K, Grandhi R, Laskowitz D, Mathew J, Hernandez A, James M, Raghunathan K, Miller J, Vavilala M, Krishnamoorthy V, investigators T. Association of early dexmedetomidine exposure with brain injury biomarker levels following moderate – Severe traumatic brain injury: A TRACK-TBI study. Journal Of Clinical Neuroscience 2024, 126: 338-347. PMID: 39029302, DOI: 10.1016/j.jocn.2024.07.003.Peer-Reviewed Original ResearchConceptsC-reactive proteinNeuron-specific enolaseGlial fibrillary acidic proteinBiomarker levelsUbiquitin C-terminal hydrolase-L1Traumatic brain injuryDexmedetomidine exposureInjury biomarkersSevere traumatic brain injuryTRACK-TBIS100 calcium-binding protein BInflammatory biomarkers C-reactive proteinCalcium-binding protein BHs-CRP levelsLevel 1 trauma centerRetrospective cohort studyCritically ill TBI patientsAlpha-2 agonistsBrain injuryBrain injury biomarkersBiomarkers C-reactive proteinModulate autonomic functionGlasgow Coma Scale score 3No significant associationSecondary brain injuryAssociation of Early Dexmedetomidine Utilization With Clinical Outcomes After Moderate-Severe Traumatic Brain Injury: A Retrospective Cohort Study
Liu S, Kelly-Hedrick M, Komisarow J, Hatfield J, Ohnuma T, Treggiari M, Colton K, Arulraja E, Vavilala M, Laskowitz D, Mathew J, Hernandez A, James M, Raghunathan K, Krishnamoorthy V. Association of Early Dexmedetomidine Utilization With Clinical Outcomes After Moderate-Severe Traumatic Brain Injury: A Retrospective Cohort Study. Anesthesia & Analgesia 2024, 139: 366-374. PMID: 38335145, PMCID: PMC11250935, DOI: 10.1213/ane.0000000000006869.Peer-Reviewed Original ResearchLength of stayTraumatic brain injuryImprove patient outcomesModerate-severe TBIRetrospective cohort studyMechanical ventilationMechanically ventilated patientsDexmedetomidine exposureDay of admissionCohort studyHospital mortalityOdds of hospital mortalityPatient outcomesAssociated with reduced oddsCohort of critically ill adult patientsPrimary outcome of hospital mortalityReduce length of stayHospital costsAssociated with oddsOutcome of hospital mortalityCritically ill adult patientsDay of ICU admissionHospital length of stayIll adult patientsPublic health problem
2023
Association of Early Dexmedetomidine Utilization With Clinical and Functional Outcomes Following Moderate-Severe Traumatic Brain Injury: A Transforming Clinical Research and Knowledge in Traumatic Brain Injury Study*
Liu S, Kelly-Hedrick M, Temkin N, Barber J, Komisarow J, Hatfield J, Ohnuma T, Manley G, Treggiari M, Colton K, Vavilala M, Grandhi R, Laskowitz D, Mathew J, Hernandez A, James M, Raghunathan K, Goldstein B, Markowitz A, Krishnamoorthy V, Investigators T. Association of Early Dexmedetomidine Utilization With Clinical and Functional Outcomes Following Moderate-Severe Traumatic Brain Injury: A Transforming Clinical Research and Knowledge in Traumatic Brain Injury Study*. Critical Care Medicine 2023, 52: 607-617. PMID: 37966330, PMCID: PMC10939970, DOI: 10.1097/ccm.0000000000006106.Peer-Reviewed Original ResearchModerate-severe traumatic brain injuryDisability Rating ScaleDexmedetomidine exposureHours of admissionTraumatic brain injuryFunctional outcomeHospital stayMechanical ventilationBrain injuryICP monitoringGlasgow Outcome Scale-ExtendedLevel 1 trauma centerClinical researchSevere traumatic brain injuryTraumatic Brain Injury (CENTER-TBI) studyFollowing secondary outcomesRetrospective cohort studySecond-line agentsPropensity-weighted modelsBrain Injury StudyLower DRS scoresEarly dexmedetomidineHospital mortalitySedation choiceUnexposed patients